From the April 2022 issue of HealthCare Business News magazine
The first MELODY robot is only in use at RWJUH now, but the technology may at some point be used in rural community hospitals, pharmacies, rehab facilities and senior living centers. Sengupta sees great potential in its ability to reduce the impact of “healthcare deserts” in small towns that are bogged by staffing shortages.
He also says it will be helpful for addressing cardiovascular disease and plans to combine the technology with new AI cardiovascular diagnostic capabilities. “Many cardiovascular diseases remain undetected for a long time and can be silent killers. Combining robotic tele-ultrasound technology with new and existing AI capabilities will provide us with a tremendous opportunity for early detection and treatment of cardiovascular disease in our communities, and help us save lives.”
Ad Statistics
Times Displayed: 46200
Times Visited: 1302 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
The solution is also being used in Europe and Canada.
DiA's ultrasound AI comparable to cardiac MR for right ventricle function analysis
At RSNA 2021 in December, DiA Imaging Analysis touted the recent validation of its AI-based ultrasound software, LVivo RV, in an independent study comparing it to cardiac MR for Right Ventricle Function (RVF) analysis.
The size and functioning of the heart’s right ventricle can indicate signs of cardiac dysfunction, including pulmonary embolism, pulmonary hypertension and right heart failure. MR is considered the gold standard for cardiac imaging, and while common, RVF analysis via ultrasound is often difficult due to the RV’s location and frequently requires additional examinations to ensure results are accurate.
DiA’s software measures the size, function and strain of the right ventricle and requires just one click, with results delivered in a few seconds in one single view. “When you do a regular echo or cardiac exam, you have to take a few views to get those results. We’re doing everything from one view and automatically. With others, you have to draw lines manually and go to different views,” DiA CEO and co-founder Hila Goldman Aslan told HCB News.
The study is titled, Validation of Artificial Intelligence for Assessing Right Ventricular Function by Transthoracic Echocardiography, and was conducted by researchers at Mount Sinai. DiA’s right heart AI solution was applied to 125 patients. CMR analysis revealed that thirty had abnormal right ventricle ejection fraction (RVEF) (24%) and 78 had abnormal left ventricle ejection fraction (LVEF) (62.4%). All those that had abnormal RVEF had abnormal LVEF.
